Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3234 vs Placebo in Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
NCT07407803Phase 3Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tunlametinib in plexiform neurofibroma (PN), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Mar 2026; status: recruiting.
02
Drugs
tunlametinib
03
Conditions
plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT07407803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407803.